CLDX Celldex Therapeutics, Inc. Loading...

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
Time Author Thesis Company / ticker Signal Since call Position Source
14:31
Sep 22
A May MD
CLDX seen much lower on CSU profile
Short CLDX as the author expects further downside beyond the current 15% drop, arguing its product profile for CSU is not marketable.
CLDX Celldex Therapeutics, Inc. Short — —
13:58
Sep 22
A May MD
Short CLDX on uncompetitive safety label
Short CLDX as two grade-4 anaphylaxis cases imply a black-box warning, in-office dosing and lab monitoring, leaving it a 4L CSU drug outcompeted by Dupixent and Rhapsido, with a practically nonexistent commercial TAM.
CLDX Celldex Therapeutics, Inc. Short 1ST — —

About CLDX Investor Commentary

Across the available history and selected sources, Buzzberg tracks CLDX (Celldex Therapeutics, Inc.) across 2 sources: 0 bullish vs 2 bearish calls from 2 authors. Historical directional balance: -29% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 7 total trade ideas tracked. Past 7 days, before deduplication: 2 other directions. Latest voices: A May MD.